Abstract
Toxic liver disease, hepatotoxicity, encompasses numerous different individual diseases that ultimately lead to progressive damage of the liver, to liver malfunction and death. Environmental toxicity, alcoholic and non-alcoholic steatohepatitis, viral hepatitis, and cirrhosis are examples of liver diseases, though not reciprocally exclusive, that can ultimately lead to fatal liver disease. In young adults, there are several factors associated with risk of liver damage, including rising rates of obesity, excessive alcohol consumption, drugs of misuse alone or in combination with drugs of use. There is an urgent need to better understand the causes of this recent rise in fatal liver disease in a population that has not been at great risk previously.
Aims: The purpose of this chapter is to provide guidance to detection and assessment of hepatotoxicity induced by human health products, toxic environmental pollutants and plant and animal toxins. This paper is promoting the safe and effective use of therapeutic products by physicians, other health care professionals as well as patients. The knowledge is applicable to pharmaceutical products for human use, natural health products and biological drugs.
This chapter is intended to provide basic considerations for the detection requirements of hepatotoxicity caused by natural health products and pharmaceutical, both alone and in the presence of other health products, foods or xenobiotics.
The investigational approach used for a particular product will depend on multiple factors, including the pharmacodynamic and pharmacokinetic characteristics of the product, the indications, the dosages and routes of administration.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ALP:
-
Alkaline phosphatase
- ALT:
-
Alanine aminotransferase (glutamic-pyruvic transaminase, SGPT)
- AST:
-
Aspartate aminotransferase (glutamic-oxaloacetic aminotransferases, SGOT)
- CB:
-
Conjugated (direct) bilirubin
- GGT:
-
γ-Glutamyltransferase (γ-glutamyltranspeptidase, GGTP)
- ICH:
-
International Conference on Harmonisation
- INR:
-
International Normalized Ratio
- TB:
-
Total bilirubin (sum of conjugated and non-conjugated serum bilirubin)
- ULN:
-
Upper limit of the normal reference range (or N)
References
Ch R. Experimental toxic injury of the liver. In: Ch R, editor. The liver. New York: Academic; 1964. p. 335–476.
Benhamou JP. Drug-induced hepatitis: clinical aspects. In: Fillastre JP, editor. Hepatotoxicity of drugs. Rouen: Universite de Rouen; 1986. p. 26–30.
Zimmerman HJ. The spectrum of hepatotoxicity. Perspect Biol Med. 1968;12:135–61.
Zimmerman HJ, Maddrey WC. Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER, editors. Diseases of the liver. Philadelphia: JB Lippincott Company; 1993. p. 707–69.
Zimmerman HJ. Hepatotoxicity: the adverse effects of drug and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 1999. Chapters 4, 5 and 16
McCuskey RS, Earnest DL. Hepatic and gastrointestinal toxicology, vol 9. In: Sipes IG, CA MQ, Gandolfi AJ, editors. Comprehensive toxicology. Cambridge: Pergamen Press; 1997.
Wieland T. Poisonous principles of mushrooms of the genus Amanita. Science. 1968;159:946.
Goldblatt LA. Aflatoxins—scientific background control and implications. New York: Academic; 1969.
Neuman MG, Eshchar J, Cotariu D, Ishay J, Barr-Nea L. Hepatotoxicity of Hornet’s venom sac extract, after repeated in vivo and in vitro envenomation. Acta Pharmacol Toxicol Scand. 1983;53:314–9.
Neuman MG, Ishay J, Zimmerman HJ, Eshchar J. Hepatotoxicity of the oriental hornet venom. Harefuah. 1990;118(2):78–80.
Teschke R, Danan G. Review: drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol. 2018;84:1467–77.
Chuttani HK, Gupta PS, Gulati S, Gupta DN. Acute copper sulfate poisoning. Am J Med. 1965;39:849.
Goldstein BD, Witz G. Benzene. In: Lippman M, editor. Environmental toxicants: human exposures and their health effects. 2nd ed. New York: Wiley Interscience; 2000. p. 121–51.
Kenna JG. Immunological allergic drug-induced hepatitis. Lessons from halothane. J Hepatol. 1997;26(Suppl):5.
Ludwig J, Kim CH, Wiesner RH, Krom RI. Floxuridine-induced sclerosing cholangitis. An ischemic cholangiopathy? Hepatology. 1989;9:215–8.
Neuman MG, French SW, Zakhari S, Malnick S, Seitz HK, Cohen LB, Salaspuro M, Voinea-Griffin A, Barasch A, Kirpich IA, Thomes PS, Schrum LW, Donohue TM Jr, Kharbanda K, Cruz M, Opris M. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol. 2017;102(1):162–80. https://doi.org/10.1016/j.yexmp.2017.01.003.
Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731–9.
Hoofnagle JH, Carithers RL, Shapiro C, Ascher N. Fulminant hepatic failure. Summary of a workshop. Hepatology. 1995;21:240–52.
Zafrani E, Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med. 1983;143:195–200.
Daly A. Drug-induced liver injury: past, present and future. Pharmacogenomics. 2010;11:607–11.
Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol. 2005;33(1):155–64.
Rappaport AM. Acinar units and pathophysiology of the liver. In: Rouiller C, editor. The liver, vol. I. New York: Academic; 1963. p. 265–328.
Zimmerman HJ, Ishak KG. Hepatic injury due to drugs and toxins. In: MacSween RNM, Anthony PP, Scheuer PJ, Burt AD, Portman BC, editors. Pathology of the liver. 3rd ed. Edinburgh: Churchill- Livingstone; 1994. p. 563–634.
Ishak KG, Mullick FG. Drug-induced and toxic injury. In: Peters RL, Craig JR, editors. Liver pathology. New York: Churchill-Livingstone; 1986. p. 221–54.
Neuman MG, Winkler R. Veno-occlusive disease of the liver induced by traditional herbal medicine Roumanian. J Rev Hepatol. 2008;4(2):3, 7-9.
Loyke HF. Experimental hypertension treated with CCl4: measurement of adrenal function, vascular responsiveness, and angiotensinase converting enzyme. Proc Soc Exp Biol Med. 1964;115:1035.
Andrade RJ, Robles M, Lucena MI. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf. 2009;8(6):709–14.
Watkins PB. Role of cytochrome P450 in drug metabolism and hepatotoxicity. Semin Liver Dis. 1990;10:235–50.
Plaa GL, Hewitt WR. Quantitative evaluation of indices of hepatotoxicity. In: Plaa GL, Hewitt WR, editors. Toxicology of the liver. New York: Raven Press; 1982. p. 103–20.
Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin No Am. 1995;24:759–78.
Wilke RA, Reif DM, Moore JH. Combinatorial pharmacogenetics. Nature Rev Drug Discov. 2005;4:911–8.
Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci. 2001;22:298–305.
Severino G, Del Zompo M. Adverse drug reactions: role of pharmacogenomics. Pharmacol Res. 2004;49:363–73.
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.
Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Gen. 2006;16:873–9.
Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology. 2001;33:1009–13.
Neuman MG. Apoptosis in liver disease. Rom J Gastroenterol. 2002;11(1):3–7.
Phillips MJ, Latham PS, Poucell-Halton S. Electron microscopy of human liver disease. In: Schiff L, Schiff ER, editors. Diseases of the liver. 7th ed. Philadelphia: J.B. Lippincott; 1993. p. 189–216.
Apostolova N, Lj G-S, Moran A, Alvarez A, Blas-Garcia A, Esplugues J. Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol. 2010;160(8):2069–84.
Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin Drug Metab Toxicol. 2009;5(5):463–73.
De Bus L, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J, Benoit D, Vogelaers D, Van Vlierberghe H. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010;6(3):322–6.
Jones DP, Lemasters JJ, Han D, Boelsterli UA, Kaplowitz N. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol Interv. 2010;10(2):98–111.
Kaplowitz N, LD DL. Drug-induced hepatic disease. New York: Marcel Decker Inc; 2003.
Lucena MI, Garca-Martín E, Andrade RJ, Martínez C, Stephens C, Ruiz JD, Ulzurrun E, Fernandez MC, Romero-Gomez M, Castiella A, Planas R, Durán JA, De Dios AM, Guarner C, Soriano G, Borraz Y, Agundez JA. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology. 2010;52(1):303–12.
Neuman MG. Cytokines and Inflamed Liver. Clin Biochem. 1999;33:601–5.
Lewis J. ‘Hy’s law’, the ‘Rezulin Rule’ and other predictors of severe drug-induced hepatotoxicity; putting risk-benefit into perspective. Pharmacoepiol Drug Safety. 2006;15:221–9.
Neuman MG, Malkiewicz IM, Shear NH. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem. 2000;33(7):517–24.
Neuman MG, Shear NH, Jacobson-Brown PM, Katz GG, Neilson HK, Malkiewicz IM, Cameron RG, Abbott F. CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity. Clin Biochem. 2001;34(3):211–8.
Krivoy N, Taeri M, Neuman MG. Antiepileptic drug-induced hypersensitivity syndrome reactions mechanisms. Curr Drug Safety. 2006;1(3):289–99.
Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol. 2000;33(6):949–52.
Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–30.
Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52(2):730–42.
Food and Drug Administration Warning Working Group. Nonclinical assessment of potential hepatotoxicity in man. p. 1–12, appendix, November 2000. Food and Drug Administration Warning Working Group. Clinical white paper. November 2000.
Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474–85.
Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26(3):664–9.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
European Medicines Agency, Committee for Medicinal Products for Human Use, Draft Guideline on Detection of Early Signals of Drug-induced Hepatotoxicity in Non-clinical Studies. Doc. Ref. EMEA/CHMP/SWP/150115/2006. 2006.
Food and Drug Administration Warning. 2004. www.fda.gov/medwatch/SAFETY/2004/Viramune_PI.pdf
Food and Drug Administration. Warning concept paper. Premarketing evaluation of drug-induced liver injury. 2007.
Food and Drug Administration. Guidance for industry, drug-induced liver injury: premarketing clinical evaluation. 2009.
McLean EK. The toxic actions of pyrrolizidine (Senecio) alkaloids. Pharmacol Rev. 1970;22:429–83.
Neuman MG, Cameron RG, Shear NH, Feuer G. Drug-induced apoptosis of skin cells and liver. In: Cameron RG, Fauer G, editors. Handbook of experimental pharmacology: apoptosis modulation by drugs. Vol. 142, Chapter 13. Heidelberg: Springer Verlag Publishers; 1999. p. 344–55.
Neuman MG, Cohen L, Opris M, Nanau RM, Jeong H. Hepatotoxicity of pyrrolizidine alkaloids. J Pharm Pharm Sci. 2015;18(4):825–43.
Neuman MG, Ishay J, Zimmerman HJ, Eshchar J. Hepatotoxicity of Vespa orientalis venom sac extract. Pharmacol Toxicol. 1991;69(1):1–36.
Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J, Zimmermann A, Oneta CM. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol. 2007;47(4):521–6.
Fischl J. Aminoaciduria in thallium poisoning. Am J Med Sci. 1966;251:40.
Luongo MA, Bjornson SS. The liver in ferrous sulfate poisoning. A report of three fatal cases in children and an experimental study. N Engl J Med. 1954;251:995.
Bagberi SA, Boyer JL. Peliosis hepatis associated with androgen-anabolic steroid therapy. A severe form of hepatic injury. Ann Intern Med. 1974;81:6100618.
Benjamin SB, Ishak KG, Zimmerman H, Agron M. Phenylbutazone liver injury: a clinical pathologic survey of 23 cases and review of the of the literature. Hepatology. 1981;1:255–63.
McLean AEM, McLean ER, Judah JD. Cellular necrosis in the liver induced and modified by drugs. Internat Rev Exp Pathol. 1965;4:127.
Schiodt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in a urban county hospital. N Engl J Med. 1997;337:112–7.
Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet. 1995;346:547–52.
Wendel A, Feuerstein S, Konz KH. Acute paracetamol intoxication of starved mice leads to lipid peroxidation in vivo. Biochem Pharmacol. 1979;28:2051.
Artwohl JE, Henne-Bruns O, Carter E, Cara LM. Acetaminophen toxicosis: a potential model for liver failure in swine. Vet Hum Toxicol. 1988;30:324.
Zimmerman HJ. Effects of aspirin and acetaminophen on the liver. Arch Intern Med. 1981;141:333–8.
Zimmmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol. Analysis of instances of a therapeutic misadventure. Hepatology. 1995;22:767–2.
Schiano TD. Liver injury from herbs and other botanicals. Clin Liver Dis. 1998;2:607–36.
Javaid A, Bonkovsky HL. Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J Hepatol. 2006;45(2):334–5.
Jimenez-Saenz M, Martinez-Sanchez MC. Acute hepatitis associated with the use of green tea infusions. J Hepatol. 2006;44(3):616–7.
Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, Huang WY, Nashan B, Peltekian K. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl. 2006;12(12):1892–5.
Teschke R, Andrade RJ. Special Issue “Drug, Herb, and Dietary Supplement Hepatotoxicity”. Int J Mol Sci. 2016;17(9):1488. https://doi.org/10.3390/ijms17091488.
Cornish HM, Block WD. A study of carbon tetrachloride. II. The effect of carbon tetrachloride on serum and tissue enzymes. Arch Environ Hlth. 1960;1:96.
Kosrud GO, Price HG, McLaughlin JM. Sensitivity of several serum enzymes in detecting carbon tetrachloride-induced liver damage in rats. Toxicol Appl Pharmacol. 1972;22:474.
Fox CF, Dinman BD, Frajola WJ. CCl4 poisoning. II. Serum enzymes, free fatty acids and liver pathology: effects of phenoxybenzamine and phenergan. Proc Soc Exp Biol Med. 1962;111:731.
Recknagel RO. Carbon tetrachloride hepatotoxicity. Pharmacol Rev. 1967;19:145.
Recknagel RO, Glende EA Jr. Carbon tetrachloride hepatotoxicity: an example of lethal cleavage. CRC Crit Rev Toxicol. 1973;2:263.
Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2′3'dideoxyinosine (ddI). Ann Intern Med. 1991;165:382–284.
Davis DC, Hashimoto M, Gillette JR. Effects of bromobenzene and carbon tetrachloride on the synthesis and release of proteins by the perfused rat liver. Biochem Pharmacol. 1973;22:1989.
Althausen TL, Thoenes E. Influence on carbohydrate metabolism of experimentally induced hepatic changes in phosphorus poisoning. Arch Intern Med. 1932;50:58.
Suzuki S, Ogawa W, Shibata KL, Tsuzuki H. Changes in Zn and Fe metabolism and carbonic anhydrase and catalase activity in animals with liver damage by carbon tetrachloride or ethionine. Jpn J Pharmacol. 1967;17:393.
Gumucio JJ, Katz ME, Miller DL, et al. Bile salt transport after selective damage to acinar zone 3 hepatocytes by bromobenzene in the rat. Toxicol Appl Pharmacol. 1979;50:77.
Haddad P, Gascon-Barr M, Dumont A. Comparative hepatic response to bromobenzene and allyl alcohol in the vitamin D-replete and vitamin D depleted rat. J Pharmacol Exp Ther. 1985;233:499.
Mallory FB. Phosphorous poisoning and alcoholic cirrhosis. Am J Pathol. 1933;9:557.
Rojkind A. Collagen metabolism in the liver. In: Hall P, editor. Alcoholic liver disease pathobiology, epidemiology and clinical aspects. London: Edward Arnold; 1985. p. 90–112.
Maker JJ, Friedman SL. Pathogenesis of hepatic fibrosis. In: Hall P, editor. Alcoholic liver disease. 2nd ed. London: Edward Arnold; 1995. p. 71–8.
Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med. 1986;104:399–404.
Neuman MG, Cohen LB, Steenkamp V. Pyrrolizidine alkaloids enhance alcohol-induced hepatocytotoxicity in vitro in normal human hepatocytes. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):53–68.
Katz GG, Shear NH, Malkiewicz IM, Valentino K, Neuman MG. Signaling for ethanol-induced apoptosis and repair in vitro. Clin Biochem. 2001;34:219–27.
Malnick S, Maor Y, Melzer E, Ziv-Sokolowskaia N, Neuman MG. Severe hepatotoxicity link to denosumab. Eur Rev Med Pharmacol Sci. 2017;21(1):78–85.
Acknowledgements
All the micrographs presented are cases that consulted Dr. Neuman and belong to In Vitro Drug Safety and Biotechnology.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Self Study
Self Study
1.1 Questions and Answers
Which statement is true
-
1.
Acetaminophen at therapeutic concentration taken concomitantly with alcohol in normal doses is
-
(a)
not harmful
-
(b)
a deadly combination
Response correct (b)
-
(a)
-
2.
In drug-induced hepatitis, which of the following is correct?
-
(a)
ALT is higher than AST
-
(b)
AST is higher than ALT
Response correct (a)
-
(a)
-
3.
Herbal and complementary medicine may produce:
-
(a)
Liver damage
-
(b)
Enhancement of liver function
-
(c)
Liver failure
-
(d)
All of the above
Response correct (a)
-
(a)
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Neuman, M.G. (2020). Hepatotoxicity: Mechanisms of Liver Injury. In: Radu-Ionita, F., Pyrsopoulos, N., Jinga, M., Tintoiu, I., Sun, Z., Bontas, E. (eds) Liver Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-24432-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-24432-3_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-24431-6
Online ISBN: 978-3-030-24432-3
eBook Packages: MedicineMedicine (R0)